Table 2. Open in new tab Correlation of...

NMDAS Question	Height SD	BMI SD
Psychiatric involvement	−0.10	−0.19 to −0.02	0.016	545	−0.06	−0.15 to 0.03	0.193	447
Cerebellar ataxia	−0.20	−0.28 to −0.11	<0.001^a	536	−0.06	−0.15 to 0.04	0.238	442
Migraine	−0.10	−0.18 to −0.01	0.026	545	−0.10	−0.19 to 0.00	0.039	447
Cognition	−0.28	−0.36 to −0.20	<0.001^a	515	−0.13	−0.22 to −0.04	0.007	426
Neuropathy	−0.01	−0.10 to 0.07	0.785	538	0.07	−0.02 to 0.16	0.128	443
Dysphonia or dysarthria	−0.13	−0.22 to −0.05	0.002	539	−0.16	−0.25 to −0.07	0.001^a	442
Seizures	−0.08	−0.16 to 0.00	0.065	545	−0.21	−0.30 to −0.12	<0.001^a	447
Encephalopathy	−0.09	−0.18 to −0.01	0.031	545	−0.22	−0.31 to −0.13	<0.001^a	447
Strokelike episodes	−0.10	−0.18 to −0.01	0.025	545	−0.22	−0.31 to −0.13	<0.001^a	447
Pyramidal	−0.19	−0.27 to −0.11	<0.001^a	537	−0.11	−0.20 to −0.02	0.017	443
Extrapyramidal	−0.13	−0.21 to −0.05	0.002	537	−0.02	−0.12 to 0.07	0.604	443
Visual acuity	−0.12	−0.21 to −0.04	0.005	529	0.09	0.00 to 0.19	0.049	435
Ptosis	−0.01	−0.10 to 0.07	0.747	539	0.08	−0.01 to 0.18	0.075	443
CPEO	0.02	−0.07 to 0.10	0.701	540	0.05	−0.04 to 0.14	0.288	443
Hearing impairment	−0.24	−0.32 to −0.16	<0.001^a	545	−0.17	−0.26 to −0.08	<0.001^a	447
Gastrointestinal disturbance	−0.17	−0.25 to −0.08	<0.001^a	545	−0.17	−0.26 to −0.08	<0.001^a	447
Myopathy	−0.07	−0.15 to 0.02	0.119	540	−0.10	−0.19 to −0.01	0.031	443
Diabetes	−0.19	−0.27 to −0.10	<0.001^a	545	0.02	−0.07 to 0.11	0.649	447
Cardiovascular involvement	−0.21	−0.29 to −0.12	<0.001^a	495	−0.07	−0.16 to 0.03	0.170	414

NMDAS Question

Height SD

BMI SD

95% CI

Psychiatric involvement

−0.10

−0.19 to −0.02

0.016

545

−0.06

−0.15 to 0.03

0.193

447

Cerebellar ataxia

−0.20

−0.28 to −0.11

<0.001^a

536

−0.06

−0.15 to 0.04

0.238

442

Migraine

−0.10

−0.18 to −0.01

0.026

545

−0.10

−0.19 to 0.00

0.039

447

Cognition

−0.28

−0.36 to −0.20

<0.001^a

515

−0.13

−0.22 to −0.04

0.007

426

Neuropathy

−0.01

−0.10 to 0.07

0.785

538

0.07

−0.02 to 0.16

0.128

443

Dysphonia or dysarthria

−0.13

−0.22 to −0.05

0.002

539

−0.16

−0.25 to −0.07

0.001^a

442

Seizures

−0.08

−0.16 to 0.00

0.065

545

−0.21

−0.30 to −0.12

<0.001^a

447

Encephalopathy

−0.09

−0.18 to −0.01

0.031

545

−0.22

−0.31 to −0.13

<0.001^a

447

Strokelike episodes

−0.10

−0.18 to −0.01

0.025

545

−0.22

−0.31 to −0.13

<0.001^a

447

Pyramidal

−0.19

−0.27 to −0.11

<0.001^a

537

−0.11

−0.20 to −0.02

0.017

443

Extrapyramidal

−0.13

−0.21 to −0.05

0.002

537

−0.02

−0.12 to 0.07

0.604

443

Visual acuity

−0.12

−0.21 to −0.04

0.005

529

0.09

0.00 to 0.19

0.049

435

Ptosis

−0.01

−0.10 to 0.07

0.747

539

0.08

−0.01 to 0.18

0.075

443

CPEO

0.02

−0.07 to 0.10

0.701

540

0.05

−0.04 to 0.14

0.288

443

Hearing impairment

−0.24

−0.32 to −0.16

<0.001^a

545

−0.17

−0.26 to −0.08

<0.001^a

447

Gastrointestinal disturbance

−0.17

−0.25 to −0.08

<0.001^a

545

−0.17

−0.26 to −0.08

<0.001^a

447

Myopathy

−0.07

−0.15 to 0.02

0.119

540

−0.10

−0.19 to −0.01

0.031

443

Diabetes

−0.19

−0.27 to −0.10

<0.001^a

545

0.02

−0.07 to 0.11

0.649

447

Cardiovascular involvement

−0.21

−0.29 to −0.12

<0.001^a

495

−0.07

−0.16 to 0.03

0.170

414

NMDAS Question	Height SD	BMI SD
Psychiatric involvement	−0.10	−0.19 to −0.02	0.016	545	−0.06	−0.15 to 0.03	0.193	447
Cerebellar ataxia	−0.20	−0.28 to −0.11	<0.001^a	536	−0.06	−0.15 to 0.04	0.238	442
Migraine	−0.10	−0.18 to −0.01	0.026	545	−0.10	−0.19 to 0.00	0.039	447
Cognition	−0.28	−0.36 to −0.20	<0.001^a	515	−0.13	−0.22 to −0.04	0.007	426
Neuropathy	−0.01	−0.10 to 0.07	0.785	538	0.07	−0.02 to 0.16	0.128	443
Dysphonia or dysarthria	−0.13	−0.22 to −0.05	0.002	539	−0.16	−0.25 to −0.07	0.001^a	442
Seizures	−0.08	−0.16 to 0.00	0.065	545	−0.21	−0.30 to −0.12	<0.001^a	447
Encephalopathy	−0.09	−0.18 to −0.01	0.031	545	−0.22	−0.31 to −0.13	<0.001^a	447
Strokelike episodes	−0.10	−0.18 to −0.01	0.025	545	−0.22	−0.31 to −0.13	<0.001^a	447
Pyramidal	−0.19	−0.27 to −0.11	<0.001^a	537	−0.11	−0.20 to −0.02	0.017	443
Extrapyramidal	−0.13	−0.21 to −0.05	0.002	537	−0.02	−0.12 to 0.07	0.604	443
Visual acuity	−0.12	−0.21 to −0.04	0.005	529	0.09	0.00 to 0.19	0.049	435
Ptosis	−0.01	−0.10 to 0.07	0.747	539	0.08	−0.01 to 0.18	0.075	443
CPEO	0.02	−0.07 to 0.10	0.701	540	0.05	−0.04 to 0.14	0.288	443
Hearing impairment	−0.24	−0.32 to −0.16	<0.001^a	545	−0.17	−0.26 to −0.08	<0.001^a	447
Gastrointestinal disturbance	−0.17	−0.25 to −0.08	<0.001^a	545	−0.17	−0.26 to −0.08	<0.001^a	447
Myopathy	−0.07	−0.15 to 0.02	0.119	540	−0.10	−0.19 to −0.01	0.031	443
Diabetes	−0.19	−0.27 to −0.10	<0.001^a	545	0.02	−0.07 to 0.11	0.649	447
Cardiovascular involvement	−0.21	−0.29 to −0.12	<0.001^a	495	−0.07	−0.16 to 0.03	0.170	414

Table 2.

Open in new tab

Correlation of Height and BMI SDs With Disease Manifestations

NMDAS Question	Height SD				BMI SD
NMDAS Question	r	95% CI	P	n	r	95% CI	P	n
Psychiatric involvement	−0.10	−0.19 to −0.02	0.016	545	−0.06	−0.15 to 0.03	0.193	447
Cerebellar ataxia	−0.20	−0.28 to −0.11	<0.001^a	536	−0.06	−0.15 to 0.04	0.238	442
Migraine	−0.10	−0.18 to −0.01	0.026	545	−0.10	−0.19 to 0.00	0.039	447
Cognition	−0.28	−0.36 to −0.20	<0.001^a	515	−0.13	−0.22 to −0.04	0.007	426
Neuropathy	−0.01	−0.10 to 0.07	0.785	538	0.07	−0.02 to 0.16	0.128	443
Dysphonia or dysarthria	−0.13	−0.22 to −0.05	0.002	539	−0.16	−0.25 to −0.07	0.001^a	442
Seizures	−0.08	−0.16 to 0.00	0.065	545	−0.21	−0.30 to −0.12	<0.001^a	447
Encephalopathy	−0.09	−0.18 to −0.01	0.031	545	−0.22	−0.31 to −0.13	<0.001^a	447
Strokelike episodes	−0.10	−0.18 to −0.01	0.025	545	−0.22	−0.31 to −0.13	<0.001^a	447
Pyramidal	−0.19	−0.27 to −0.11	<0.001^a	537	−0.11	−0.20 to −0.02	0.017	443
Extrapyramidal	−0.13	−0.21 to −0.05	0.002	537	−0.02	−0.12 to 0.07	0.604	443
Visual acuity	−0.12	−0.21 to −0.04	0.005	529	0.09	0.00 to 0.19	0.049	435
Ptosis	−0.01	−0.10 to 0.07	0.747	539	0.08	−0.01 to 0.18	0.075	443
CPEO	0.02	−0.07 to 0.10	0.701	540	0.05	−0.04 to 0.14	0.288	443
Hearing impairment	−0.24	−0.32 to −0.16	<0.001^a	545	−0.17	−0.26 to −0.08	<0.001^a	447
Gastrointestinal disturbance	−0.17	−0.25 to −0.08	<0.001^a	545	−0.17	−0.26 to −0.08	<0.001^a	447
Myopathy	−0.07	−0.15 to 0.02	0.119	540	−0.10	−0.19 to −0.01	0.031	443
Diabetes	−0.19	−0.27 to −0.10	<0.001^a	545	0.02	−0.07 to 0.11	0.649	447
Cardiovascular involvement	−0.21	−0.29 to −0.12	<0.001^a	495	−0.07	−0.16 to 0.03	0.170	414

NMDAS Question	Height SD				BMI SD
NMDAS Question	r	95% CI	P	n	r	95% CI	P	n
Psychiatric involvement	−0.10	−0.19 to −0.02	0.016	545	−0.06	−0.15 to 0.03	0.193	447
Cerebellar ataxia	−0.20	−0.28 to −0.11	<0.001^a	536	−0.06	−0.15 to 0.04	0.238	442
Migraine	−0.10	−0.18 to −0.01	0.026	545	−0.10	−0.19 to 0.00	0.039	447
Cognition	−0.28	−0.36 to −0.20	<0.001^a	515	−0.13	−0.22 to −0.04	0.007	426
Neuropathy	−0.01	−0.10 to 0.07	0.785	538	0.07	−0.02 to 0.16	0.128	443
Dysphonia or dysarthria	−0.13	−0.22 to −0.05	0.002	539	−0.16	−0.25 to −0.07	0.001^a	442
Seizures	−0.08	−0.16 to 0.00	0.065	545	−0.21	−0.30 to −0.12	<0.001^a	447
Encephalopathy	−0.09	−0.18 to −0.01	0.031	545	−0.22	−0.31 to −0.13	<0.001^a	447
Strokelike episodes	−0.10	−0.18 to −0.01	0.025	545	−0.22	−0.31 to −0.13	<0.001^a	447
Pyramidal	−0.19	−0.27 to −0.11	<0.001^a	537	−0.11	−0.20 to −0.02	0.017	443
Extrapyramidal	−0.13	−0.21 to −0.05	0.002	537	−0.02	−0.12 to 0.07	0.604	443
Visual acuity	−0.12	−0.21 to −0.04	0.005	529	0.09	0.00 to 0.19	0.049	435
Ptosis	−0.01	−0.10 to 0.07	0.747	539	0.08	−0.01 to 0.18	0.075	443
CPEO	0.02	−0.07 to 0.10	0.701	540	0.05	−0.04 to 0.14	0.288	443
Hearing impairment	−0.24	−0.32 to −0.16	<0.001^a	545	−0.17	−0.26 to −0.08	<0.001^a	447
Gastrointestinal disturbance	−0.17	−0.25 to −0.08	<0.001^a	545	−0.17	−0.26 to −0.08	<0.001^a	447
Myopathy	−0.07	−0.15 to 0.02	0.119	540	−0.10	−0.19 to −0.01	0.031	443
Diabetes	−0.19	−0.27 to −0.10	<0.001^a	545	0.02	−0.07 to 0.11	0.649	447
Cardiovascular involvement	−0.21	−0.29 to −0.12	<0.001^a	495	−0.07	−0.16 to 0.03	0.170	414

Pearson correlations of height SD and BMI SD with comorbidities as defined by individual NMDAS questions. Estimated Pearson correlation coefficients and uncorrected P values are shown. The Bonferroni corrected threshold of significance for correlations is 0.001 because 38 independent tests were performed. Disease manifestations represent answers to questions from sections II and III of the NMDAS assessment, because these are physician assessed and therefore more likely to be objective. Hearing impairment from section I was included, because this is the only assessment of this common mitochondrial disease manifestation within the NMDAS.

Significant results.

This Feature Is Available To Subscribers Only